Mirae Asset Global Investments Co. Ltd. Has $13.67 Million Position in Kenvue Inc. (NYSE:KVUE)

Mirae Asset Global Investments Co. Ltd. raised its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 41.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 576,849 shares of the company's stock after buying an additional 170,382 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Kenvue were worth $13,671,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Fulton Bank N.A. lifted its holdings in Kenvue by 0.6% in the first quarter. Fulton Bank N.A. now owns 78,888 shares of the company's stock valued at $1,892,000 after buying an additional 465 shares during the period. Scott & Selber Inc. raised its position in shares of Kenvue by 0.4% in the 1st quarter. Scott & Selber Inc. now owns 106,621 shares of the company's stock worth $2,557,000 after acquiring an additional 475 shares in the last quarter. SRS Capital Advisors Inc. lifted its stake in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after purchasing an additional 571 shares during the period. Keystone Financial Group lifted its stake in shares of Kenvue by 4.8% in the 4th quarter. Keystone Financial Group now owns 12,736 shares of the company's stock valued at $272,000 after purchasing an additional 578 shares during the period. Finally, Transatlantique Private Wealth LLC boosted its position in shares of Kenvue by 5.7% during the 4th quarter. Transatlantique Private Wealth LLC now owns 10,680 shares of the company's stock valued at $228,000 after purchasing an additional 580 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $20.89 on Monday. The firm's 50-day simple moving average is $22.80 and its two-hundred day simple moving average is $22.35. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86. Kenvue Inc. has a 52 week low of $13.76 and a 52 week high of $25.17. The firm has a market cap of $40.07 billion, a price-to-earnings ratio of 37.97, a P/E/G ratio of 3.24 and a beta of 0.98.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The business's revenue for the quarter was down 3.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.28 EPS. As a group, equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.93%. The ex-dividend date was Wednesday, May 14th. Kenvue's dividend payout ratio is presently 149.09%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on KVUE. Canaccord Genuity Group lifted their target price on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. UBS Group boosted their target price on shares of Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Friday, May 9th. Evercore ISI initiated coverage on shares of Kenvue in a report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price target for the company. Citigroup reiterated a "neutral" rating on shares of Kenvue in a report on Friday, June 13th. Finally, Redburn Atlantic initiated coverage on shares of Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective on the stock. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.